Responses
Poster Session
New therapies and therapeutic targets – SLE
90 Safety, efficacy and transcriptional changes following repeated administration of dapirolizumab pegol in patients with systemic lupus erythematosus: results from a phase i study
Compose a Response to This Article
Other responses
No responses have been published for this article.